Axsome Therapeutics, Inc.

AXSM

US05464T1043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
72.5 ^USD	-1.60%		-3.07%	-8.91%

May. 08	Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating	MT
May. 07	Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating	MT

Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 06, 2023 at 07:06 am EST

Axsome Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 57.79 million compared to USD 16.85 million a year ago. Net loss was USD 62.2 million compared to USD 44.82 million a year ago. Basic loss per share from continuing operations was USD 1.32 compared to USD 1.07 a year ago.
For the nine months, revenue was USD 199.07 million compared to USD 25.67 million a year ago. Net loss was USD 140.59 million compared to USD 125.89 million a year ago. Basic loss per share from continuing operations was USD 3.14 compared to USD 3.17 a year ago.

Latest news about Axsome Therapeutics, Inc.

Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating	May. 08	MT
Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating	May. 07	MT
Transcript : Axsome Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell	May. 06	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M	May. 06	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	May. 06	DJ
North American Morning Briefing : More Earnings -2-	Apr. 30	DJ
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says	Apr. 29	MT
Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90	Apr. 29	MT
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	Apr. 02	MT
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	Apr. 01	CI
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating	Mar. 28	MT
HC Wainwright Adjusts Axsome Therapeutics' Price Target to $190 From $180, Keeps Buy Rating	Mar. 26	MT
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating	Mar. 26	MT
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating	Mar. 26	MT
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	Mar. 25	MT
Transcript : Axsome Therapeutics, Inc. - Special Call	Mar. 25
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	Mar. 25	CI
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	Mar. 25	RE
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	Mar. 25	CI
Baird Initiates Axsome Therapeutics With Outperform Rating, Price Target is $108	Mar. 19	MT
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	Mar. 19	CI
Axsome Therapeutics Insider Sold Shares Worth $2,257,449, According to a Recent SEC Filing	Mar. 18	MT
Mizuho Cuts PT on Axsome Therapeutics to $108 From $112 After Release of AD Agitation Study Data Faces Delays, Keeps Buy Rating	Feb. 26	MT

Chart Axsome Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Sector

Pharmaceuticals

Calendar

2024-05-14 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Axsome Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

72.5 USD

Average target price

123.6 USD

Spread / Average Target

+70.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AXSOME THERAPEUTICS, INC.	-8.91%	3.44B
CSL LIMITED	-2.63%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B
BIOGEN INC.	-14.40%	32.25B
UCB	+55.89%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B
INCYTE CORPORATION	-15.50%	11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B

Biopharmaceuticals